Clinical Trials Logo

Lymphatic Metastasis clinical trials

View clinical trials related to Lymphatic Metastasis.

Filter by:

NCT ID: NCT06358222 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan

Start date: December 15, 2023
Phase:
Study type: Observational

This is a single center, prospective and observational study conducted in three stages to predict the NSCLC lymph node metastasis based on ctDNA/specific methylation molecular features combined with PET-CT imaging features and intervention study.

NCT ID: NCT06341725 Terminated - Clinical trials for Pancreatic Adenocarcinoma

EUS Role in Non-metastatic Pancreatic Adenocarcinoma Lymph Nodes Staging

Start date: February 15, 2018
Phase:
Study type: Observational

Aim of the study will be to investigate if Endoscopic Ultrasound (EUS) with elastography can be purposed between the routine staging examinations in patients with pancreatic adenocarcinoma without distant metastasis for the staging of lymph nodes status ("N" in TNM classification) - in RESECTABLE pancreatic cancer the investigators will evaluate the concordance with EUS elastography and histological findings of lymph nodes obtained during surgery, in order to assess the sensibility, specificity and the positive and negative predictive value of EUS with elastography, the disease-free survival, the percentage of metastatic patients and the overall survival (in patients with or without metastatic lymph nodes). - in "BORDERLINE resectable" and UNRESECTABLE non-metastatic ("advanced" locally") disease, the investigators will evaluate if the malignant lymph nodes samples during EUS with elastography and fine needle aspiration (FNA) will be related to a decreased survival. Secondary aim will be to register the prognosis (in terms of survival) of the patients with para-aortic and mediastinal pathological lymph nodes (related to a decreases survival in some series in literature)

NCT ID: NCT06339307 Recruiting - Gastric Cancer Clinical Trials

A Prospective Clinical Study to Validate a Preoperative Risk Scoring Model for LNM in GC Patients

Start date: February 15, 2024
Phase:
Study type: Observational

In our prior research, a risk scoring model for the occurrence of lymph node metastasis in patients who underwent radical gastrectomy for gastric cancer was established. To further validate this scoring model, a prospective study has been designed with the aim of prospectively assessing the model's clinical applicability.

NCT ID: NCT06292052 Recruiting - Lung Cancer Clinical Trials

Relation Between Tumor-draining Lymph Nodes Metastasis Pattern and Non-small Cell Lung Cancer Neoadjuvant Immunotherapy Effectiveness

Start date: January 1, 2017
Phase:
Study type: Observational

The goal of this retrospective cohort analysis is to discover the impact of the involvement extent of tumor-draining lymph nodes (TDLNs) in patients who received neoadjuvant immunochemotherapy. The main question it aims to answer is the role of TDLN in the prediction of treatment effectiveness. Researches will compare tumor-draining lymph nodes metastasis (mTDLNs) group and non-draining lymph nodes metastasis (mNDLNs) group to see whether different metastatic patterns of mediastinal lymph nodes can indicate the treatment effectiveness.

NCT ID: NCT06290739 Recruiting - Clinical trials for Intrahepatic Cholangiocarcinoma

A Machine-learning Model to Predict Lymph Node Metastasis of Intrahepatic Cholangiocarcinoma

Start date: February 7, 2024
Phase:
Study type: Observational

The object of this study is to develop a model for prediction of lymph node metastasis among intrahepatic cholangiocarcinoma (ICC) patients. Intrahepatic cholangiocarcinoma is the second most common kind of primary liver cancer, accounting for approximately 10%-15%. There is a lack of agreement regarding the necessity of performing lymph node dissection (LND) in patients with ICC. Currently, the percentage of LND is below 50%, and the rate of sufficient LND (≥6) has plummeted to less than 20%. Consequently, a large proportion of patients are unable to acquire LN status, which hinders the following systematic treatment strategies after surgery:. Therefore, our objective is to construct a LN metastasis model utilizing machine learning techniques, including patients' clinical data and pathology information, with the goal of offering a reference for patients who have not undergone LND or have had inadequate LND.

NCT ID: NCT06273501 Enrolling by invitation - Vulvar Cancer Clinical Trials

MRI and Magnetometer-guided Sentinel Lymph Node Detection in Vulvar Cancer

POSVUC
Start date: March 24, 2022
Phase: N/A
Study type: Interventional

The aim of the feasibility study is to evaluate whether SPIO-MRI and a magnetometer could be a potential substitute to the routine dual technique in pre-and intraoperative SLN localization. Secondary, to explore if SPIO-MRI could predict lymph node status in comparison to histopathological analysis.

NCT ID: NCT06264167 Not yet recruiting - Clinical trials for Ultrasound Therapy; Complications

NODE (groiN ultrasOunD cancEr)

NODE
Start date: March 1, 2024
Phase: N/A
Study type: Interventional

This study is an open label, prospective, experimental, randomised clinical trial. The primary aim of this study is to determine whether it is feasible to randomise vulvar cancer patients into one of two treatment arms:1) surgical groin node dissection (as delivered though either a sentinel node biopsy or inguinofemoral lymph node dissection (IFL), or 2) serial high-resolution bilateral groin ultrasound surveillance and clinical examination every 2 months.

NCT ID: NCT06256185 Completed - Clinical trials for Lymph Node Metastasis

Machine Learning to Predict Lymph Node Metastasis in T1 Esophageal Squamous Cell Carcinoma

Start date: January 15, 2010
Phase: N/A
Study type: Interventional

Existing models do poorly when it comes to quantifying the risk of Lymph node metastases (LNM). This study generated elastic net regression (ELR), random forest (RF), extreme gradient boosting (XGB), and a combined (ensemble) model of these for LNM in patients with T1 esophageal squamous cell carcinoma.

NCT ID: NCT06253065 Recruiting - Prostatic Neoplasms Clinical Trials

Prospective Validation of Pathology-based Artificial Intelligence Diagnostic Model for Lymph Node Metastasis in Prostate Cancer

Start date: January 12, 2024
Phase:
Study type: Observational

The goal of this diagnostic test is to prospectively test the performance of pre-developed artificial intelligence (AI) diagnostic model for detecting pathological lymph node metastasis (LNM) of prostate cancer. Investigators had developed this AI model based on deep learning algorithms in preliminary research, and it performed well in retrospective tests. Investigators will compare the diagnostic performance (sensitivity, specificity, etc.) of the AI model and routine pathological report issued by pathologists, to see if the AI model can improve the clinical workflow of pathological evaluation of LNM in prostate cancer in the real world.

NCT ID: NCT06252129 Not yet recruiting - Lung Cancer Clinical Trials

Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens

Start date: February 2024
Phase: N/A
Study type: Interventional

Lung cancer patients undergoing upfront surgery, highly benefit from a systematic lymph node dissection in the mediastinum and in the surgical specimens. The latter is performed by the pathologist. Developing a standardized technique to dissect the lobectomy specimen has the potential of maximizing the retrieval of all N1 stations lymph nodes. The investigators believe that the adoption of such technique will improve lung cancer staging and identify a higher number of patients that qualify for adjuvant therapies.